Aprea Therapeutics (APRE) Misses Q4 EPS by 49c
Tweet
Share
E-mailGet Alerts APRE Hot Sheet
Join SI Premium – FREE
Aprea Therapeutics (NASDAQ: APRE) reported Q4 EPS of ($0.49). Revenue for the quarter came in at $210 thousand.
For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- Jefferies Downgrades BSE Limited (BSE:IN) to Underperform
- Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
